Literature DB >> 7082352

Multiple human serum binding of two thienopyridinic derivatives, ticlopidine and PCR 2362, and their distribution between HSA, alpha1-acid glycoprotein and lipoproteins.

S Glasson, R Zini, J P Tillement.   

Abstract

The binding of two drugs, ticlopidine and PCR 2362, chemically related to thienopyridin, potent antiaggregant agents, was studied in vitro to serum and to the corresponding isolated proteins, HSA, alpha 1-AGP, VLDL, LDL and HDL, using equilibrium dialysis at pH 7.4 and 37 degrees. The binding of these drugs to HSA and lipoproteins was non-saturable. The binding capacity of the lipoproteins was much greater than that of HSA and appeared to be dependent on lipid content. The binding capacities of the apoproteins were less than 10% of that observed for the native lipoproteins suggesting that drug-lipoprotein binding involves drug solubilization in the lipid phase of lipoproteins rather than a classical binding to definite sites. However drug binding to alpha 1-AGP was saturable with n = 3 for both and K = 89,000 and 33,000 for ticlopidine and PCR 2362, respectively. At physiological concentration, alpha 1-AGP binding capacity represented 15% of total serum binding capacity which could double in pathological states, in which the level of this protein is increased.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082352     DOI: 10.1016/0006-2952(82)90470-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  pH dependent binding of ligands to serum lipoproteins.

Authors:  N Simon; E Dailly; P Jolliet; J P Tillement; S Urien
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

2.  Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs.

Authors:  K Hosoe; T Mae; E Konishi; K Fujii; K Yamashita; T Yamane; T Hidaka; T Ohashi
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

3.  Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

Authors:  R Zini; D Morin; C Salvadori; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

4.  Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects.

Authors:  J Shah; P Teitelbaum; B Molony; T Gabuzda; I Massey
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

5.  Stereoselective binding of tertatolol and of 4-hydroxytertatolol to human plasma proteins.

Authors:  G Bastian; S Urien; F Brée; P Jolliet; I Rocher; O Crambes; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.